THE PURE-PLAY DERMATOLOGY CATEGORY LEADER
We deliver an innovative, science-based portfolio of premium cutting-edge brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology
Restylane® Defyne FDA-approved for chin augmentation
New approvals in China including Restylane Lyft Nose, Restylane Defyne, Restylane Lyft Lidocaine Midface
Re-energized Galderma brand identity reflecting both our 40-year heritage of innovation in dermatology and our vision for tomorrow
Positive decision for use in Europe of Alluzience®, the first ready-to-use BoNT-A neuromodulator
Renewed commitment of Cetaphil® to environmental sustainability and social impact through the Clear Skies initiative
Biostimulator Sculptra® label update in the U.S. for immediate use after reconstitution and more convenient administration. Re-launch in Europe with new administration protocol
Launch of Restylane® Eyelight™, a new solution to combat under-eye shadows
Acquisition of the award-winning Alastin Skincare®, dedicated to developing innovative and clinically-tested physician-dispensed skincare products
Exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology
Exclusive licenses for the commercialization of Epsolay® and Twyneo® in the U.S.
Presentation of new nemolizumab data reinforcing rapid onset of action and consistent relief of symptoms for people with prurigo nodularis and atopic dermatitis
Celebration of 25 years of unmatched achievement for Restylane®, the original stabilized hyaluronic acid filler
“Since launching as a stand-alone company in 2019, we have made great progress in realizing our full potential. Today, we operate as a simple, coherent and integrated dermatology company that is unique in our ability to reach the whole spectrum of consumers and healthcare professionals through a truly omni-channel, go-to-market strategy. We have oriented our business around the consumer with dermatology as our common platform.
With our complete dedication to dermatology and over 40 years of scientific innovation in this field, we are uniquely positioned for leadership and growth in this market”.
Flemming Ørnskov, M.D., MPH
Chief Executive Officer
OUR UNIQUE INTEGRATED DERMATOLOGY STRATEGY
Our unique Integrated Dermatology Strategy is a key differentiator for Galderma by creating greater consumer, patient and healthcare professional engagement, generating better customer insights and delivering continuous innovation.
It is the driving force behind our strong performance, and we believe it will continue to accelerate our financial performance and deliver on our growth ambition in the years to come.
POISED FOR GROWTH IN FAST-GROWING DERMATOLOGY MARKETS
Since becoming a stand-alone company, we have shown accelerating performance momentum. Galderma is, first and foremost, a growth story.
2021 has been another pivotal year in Galderma’s growth journey. We have established Galderma as a simple, coherent and integrated dermatology company reaching the whole spectrum of consumers and healthcare professionals through an omni-channel go-to-market strategy. Our business is oriented around the consumer with dermatology as our common platform. This is supported by our portfolio of premium positioned brands and services across three product categories, Injectable Aesthetics, Dermo-cosmetics and Therapeutic Dermatology.
Our addressable market is estimated by a leading strategy consulting firm to exceed USD 60 billion in revenues in 2020 and is expected to grow at a 10% CAGR between 2020 and 2025, driven by secular trends including rising middle-class with growing disposable incomes fueling a shift to premium brands, growing consumer awareness and sensitivity around skin health and beauty.
In Injectable Aesthetics, Dysport and Restylane are leading brands by market share globally in neuromodulators and fillers, respectively, with premium positioning in their categories supported by clear product differentiation, while Sculptra is the market leader in the rapidly-growing biostimulators category.
Our Dermo-cosmetics platform is headlined by Cetaphil, the number 1 doctor-recommended sensitive skincare brand in the U.S. with 75 years of 'white-coat' endorsement. In addition to our portfolio of regional brands, we are expanding into the physician-dispensed skincare segment with the acquisition of Alastin, the number 1 preferred skincare and the fastest growing brand in the U.S. professional skincare market in 2020.
In Therapeutic Dermatology, we are category leaders in prescription treatments for acne with Epiduo (the number 1 prescription topical acne treatment by market share in the U.S.) and for rosacea with Oracea and Soolantra (the number 1 oral and tropical treatments for rosacea by market share respectively). In over-the-counter treatments, Differin is the number 1 brand for acne by market share in the U.S., Benzac is one of the top two brands by market share in multiple markets outside the U.S., and Loceryl is the number 1 nail anti-fungal brand globally by market share.
COMMITTED TO GROWTH WITH PURPOSE IN MEDICAL AESTHETICS
We aim to inspire and empower aesthetic professionals in their work. Our Global Aesthetic Injector Network (GAIN) program supports aesthetics physicians in a variety of ways, including customer education & training, a medical affairs service, and a business service to enable them to grow their business. In 2021, we held over 6,600 training events with over 100,000 healthcare professionals attending worldwide.
DIGITALIZATION AS GROWTH CATALYST
We focus on increasing awareness over competitors, leveraging insightful data to provide tailored experiences and accelerate sales conversion. E-commerce is growing consistently and in 2021, E-commerce in our core 14 markets grew almost three times as fast as offline sales, including online sales CAGR 2019-2021 of 64% for Cetaphil in the U.S. and 44% in China.
DOUBLING DOWN ON SCIENCE
Galderma stands out as one of the few players capable of inventing, developing and bringing to market truly innovative dermatological solutions. Our integrated R&D platform unlocks benefits and synergies across all our product categories.
Galderma’s global team of over 640 R&D professionals has initiated approximately 400 clinical trials across over 20 indications since 2019 and helped us obtain 80 major regulatory approvals since January 2020. Today, we are focused on accelerating development and commercializing our late-stage product candidates to bring new solutions to market faster.
A first-in-class investigational monoclonal antibody that blocks signaling of IL-31, a cytokine that acts on pruritus but also plays a key role in skin inflammation in atopic dermatitis and prurigo nodularis, two chronic immunemediated skin conditions associated with high burden of disease.
Relabotulinumtoxin Type A
A proprietary, novel, ready-to-use, liquid formulation of investigational botulinum toxin, for the treatment of glabellar lines and lateral canthal lines.
Cetaphil Portfolio Expansion
Continuously developing new product lines to further extend the Cetaphil range and meet the needs of specific skin conditions.
OUR MANUFACTURING FOOTPRINT IS READY TO SERVE GLOBAL DEMAND
Our four manufacturing plants are strategically located in Canada, Sweden, France and Brazil, serving more than 90 countries with over 280 million units produced annually.
Our site in Uppsala, Sweden, is focused on our injectable aesthetics portfolio. Our Alby-sur-Chéran, France site serves all markets except the U.S. with topicals – both over-the-counter (OTC) and prescription medicine – and supplies brands such as Differin, Aklief and Epiduo. Our largest production site, at Baie-D’Urfé, Canada, is focused on the global supply of Cetaphil, with additional production of OTC and prescription medicine for the U.S. market. The Latin American market is predominantly served by our site in Hortolândia, Brazil.
We serve more than 90 countries globally with over 280 million units produced a year.
Over 1,600 colleagues
in manufacturing, commercial quality and supply chain functions work at our four manufacturing plants.
of our units sold are produced in-house in four manufacturing facilities.
Despite the challenges of the COVID-19 crisis, we have been able to keep all manufacturing sites operational to date.
Low Injury Rate
We have succeeded in maintaining a low global Recordable Injury Rate (1.2 per million working hours), meaning no severe, irreversible injuries were recorded.
3 of 4
factory sites use 100% renewable electricity from a combination of solar, wind, hydropower, geothermal, biofuel and biomass.
100% renewable electricity by 2024
Our fourth factory is on track to be powered by 100% renewable electricity by 2024.
Currently, more than 99% of renewable electricity is supplied to our four factories, and two are certified Carbon Neutral.
Our four factories achieved zero waste-to-landfill ahead of our initial 2020 plan.
A DEDICATED TEAM WITH A PROVEN TRACK RECORD FOCUSED ON A BROADER PURPOSE
We seek bold and sophisticated talent with the capacity to innovate, collaborate and execute across teams and geographies to deliver outstanding results, and our teams bring diverse skills, innovation and passion to their work every day. Empowering our employees to make an impact at Galderma and to pursue career growth opportunities is of paramount importance to us.
GREAT PLACE TO WORK
Galderma is recognized as “A Great Place to Work” in Australia, India, Benelux, Mexico, Columbia, Brazil, Argentina and Chile. We continue to strive to live up to this description in all our locations across the globe.
DIVERSITY & INCLUSION COUNCILS
At Galderma, diversity and inclusion have been actively embedded into our company culture. Our Global Diversity & Inclusion teams have been championing the diversity and inclusion journey by tracking progress on global key performance indicators and developing other tools to measure success.
OUR BOLD ENVIRONMENTAL, SOCIAL AND GOVERNANCE RESPONSIBILITY ROADMAP
Environmental, Social and Governance (ESG) is integral to our growth outlook and deeply rooted within all dimensions of our business ambition to become the leading dermatology company in the world. Detailed in the framework above, our ESG journey is focused on four key stakeholders: Employees, Patients & Consumers, Healthcare Professionals & Customers, and Society.